MX343184B - Composiciones farmacéuticas que comprenden derivados bisfosfonato y colecalciferol en alta dosis. - Google Patents

Composiciones farmacéuticas que comprenden derivados bisfosfonato y colecalciferol en alta dosis.

Info

Publication number
MX343184B
MX343184B MX2012002786A MX2012002786A MX343184B MX 343184 B MX343184 B MX 343184B MX 2012002786 A MX2012002786 A MX 2012002786A MX 2012002786 A MX2012002786 A MX 2012002786A MX 343184 B MX343184 B MX 343184B
Authority
MX
Mexico
Prior art keywords
cholecalciferol
pharmaceutical compositions
salts
acids
dose
Prior art date
Application number
MX2012002786A
Other languages
English (en)
Other versions
MX2012002786A (es
Inventor
Kim Jin-Sun
Lee Geun-Hyeog
Choi Byong-Sun
Kim Jae-Shin
Park Jin-Ha
O Mi-Jin
Kim Eun-Mi
Original Assignee
Hanlim Pharmaceutical Co Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanlim Pharmaceutical Co Ltd * filed Critical Hanlim Pharmaceutical Co Ltd *
Publication of MX2012002786A publication Critical patent/MX2012002786A/es
Publication of MX343184B publication Critical patent/MX343184B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona composición farmacéutica para evitar o tratar osteoporosis, para administrarse una vez al mes, la composición farmacéutica comprende un derivado bisfosfonato, tal como ácido risedrónico (o su sal) o ácido ibandrónico (o su sal), y colecalciferol, en una alta dosis. La presente invención también proporciona una composición farmacéutica para evitar o tratar osteoporosis, para ser administrada una vez al mes, la composición farmacéutica comprende: (a) gránulos que contienen colecalciferol que se obtienen al adsorber en celulosa microcristalina, una solución preparada al disolver (i) colecalciferol en una cantidad correspondiente a 24,000 a 50,000 IU; (ii) uno o más seleccionados de tocoferil acetato, butilhidroxitolueno, y butilhidroxianisol como un primer agente estabilizante; y (iii) un aglutinante en etanol o una solución acuosa de etanol, (b) manitol como un segundo agente estabilizante, y (c) ácido risedrónico o su sal o ácido ibandrónico o su sal.
MX2012002786A 2009-09-18 2010-06-17 Composiciones farmacéuticas que comprenden derivados bisfosfonato y colecalciferol en alta dosis. MX343184B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020090088480A KR101102364B1 (ko) 2009-09-18 2009-09-18 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물
PCT/KR2010/003920 WO2011034274A2 (ko) 2009-09-18 2010-06-17 비스포스포네이트 유도체 및 고용량의 콜레칼시페롤을 포함하는 약학 조성물

Publications (2)

Publication Number Publication Date
MX2012002786A MX2012002786A (es) 2012-06-25
MX343184B true MX343184B (es) 2016-10-26

Family

ID=43759131

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002786A MX343184B (es) 2009-09-18 2010-06-17 Composiciones farmacéuticas que comprenden derivados bisfosfonato y colecalciferol en alta dosis.

Country Status (8)

Country Link
EP (1) EP2478909B1 (es)
KR (1) KR101102364B1 (es)
CN (2) CN102497867B (es)
BR (1) BR112012003907A2 (es)
MA (1) MA33676B1 (es)
MX (1) MX343184B (es)
RU (1) RU2533230C2 (es)
WO (1) WO2011034274A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법
ITMI20120393A1 (it) * 2012-03-14 2013-09-15 Tiberio Bruzzese Formulazioni acquose di bisfosfonati, vitamina d e alcol benzilico adatte all'uso intramuscolare o sottocutaneo
MX350569B (es) * 2012-12-03 2017-09-11 Landsteiner Scient S A De C V Composicion farmaceutica estable para el tratamiento de osteoporosis.
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
KR20160144663A (ko) 2015-06-09 2016-12-19 최숙 제제 및 이의 제조방법
IT201600123773A1 (it) * 2016-12-06 2018-06-06 Abiogen Pharma Spa Composizione per il trattamento dell’osteoartrosi
CN108420797B (zh) * 2018-05-09 2022-05-03 南京海融制药有限公司 维生素d类似物制剂及其制备方法
KR102158375B1 (ko) * 2018-10-25 2020-09-21 단국대학교 천안캠퍼스 산학협력단 비타민 d 에멀젼 및 비스포스포네이트를 포함하는 복합 액상 제형 및 이의 골다공증 예방 또는 치료 용도
KR102211287B1 (ko) * 2018-12-21 2021-02-03 (주)휴온스 비타민 d 또는 이의 유도체를 포함하는 안정성이 개선된 액상 제제

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2963718B2 (ja) * 1990-03-06 1999-10-18 グレラン製薬株式会社 ビタミンｄ▲下３▼類含有製剤
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
KR100317935B1 (ko) 1999-10-20 2001-12-22 유승필 대사성 골질환 치료용 약제조성물 및 이의 제조방법
US20030072802A1 (en) * 2001-10-11 2003-04-17 R.T. Alamo Ventures, Inc. Sustained release topiramate
US20050070504A1 (en) 2001-12-21 2005-03-31 The Procter & Gamble Co. Risedronate compositions and their methods of use
AU2003226148A1 (en) * 2002-04-05 2003-10-27 Merck & Co., Inc. Method for inhibiting bone resorption with an alendronate and vitamin d formulation
GB0330009D0 (en) * 2003-12-24 2004-01-28 Ferrosan As Probiotic tablet formulations
KR20050110814A (ko) 2004-05-19 2005-11-24 머크 앤드 캄파니 인코포레이티드 골 흡수를 억제하기 위한 조성물 및 방법
WO2005117906A1 (en) 2004-05-19 2005-12-15 Merck & Co., Inc. Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol)
US20050261250A1 (en) 2004-05-19 2005-11-24 Merck & Co., Inc., Compositions and methods for inhibiting bone resorption
WO2008026907A1 (es) * 2006-08-29 2008-03-06 Espinosa Abdala Leopoldo De Je Composición farmacéutica que comprende ibandronato y vitamina d3 para el tratamiento de osteoporosis
KR100822133B1 (ko) 2006-11-06 2008-04-15 한미약품 주식회사 비타민 ｄ 또는 이의 유도체의 고체분산체 및비스포스포네이트를 포함하는, 골다공증 예방 또는 치료용복합제제
KR100844256B1 (ko) * 2007-03-23 2008-07-07 코오롱제약주식회사 리세드로네이트와 비타민 ｄ를 포함하는 대사성 골질환치료용 약제조성물 및 이의 제조방법
KR101230178B1 (ko) * 2010-06-10 2013-02-06 주식회사 네비팜 골다공증 예방 또는 치료용 조성물 및 이의 제조방법

Also Published As

Publication number Publication date
MA33676B1 (fr) 2012-10-01
KR101102364B1 (ko) 2012-01-03
EP2478909B1 (en) 2018-04-25
CN102497867B (zh) 2015-04-29
BR112012003907A2 (pt) 2016-03-22
CN103191138A (zh) 2013-07-10
KR20110030852A (ko) 2011-03-24
MX2012002786A (es) 2012-06-25
EP2478909A2 (en) 2012-07-25
CN102497867A (zh) 2012-06-13
RU2533230C2 (ru) 2014-11-20
RU2012109614A (ru) 2013-10-27
WO2011034274A3 (ko) 2011-05-19
WO2011034274A2 (ko) 2011-03-24
EP2478909A4 (en) 2014-02-26

Similar Documents

Publication Publication Date Title
MX343184B (es) Composiciones farmacéuticas que comprenden derivados bisfosfonato y colecalciferol en alta dosis.
PH12018500147A1 (en) Benzodiazepine derivatives as rsv inhibitors
WO2017123884A8 (en) Heterocyclic compounds as rsv inhibitors
MX2011012122A (es) Derivados de tiofeno.
WO2012054110A3 (en) Compounds and methods for inhibiting phosphate transport
WO2009155121A3 (en) Inhibitors of pi3 kinase
EP2590655A4 (en) COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT
EA033168B1 (ru) СТИМУЛЯТОРЫ sGC
NO20076215L (no) Nanopartikulaere clopidogrelformuleringer
WO2010108074A3 (en) Inhibitors of pi3 kinase
PH12017501185A1 (en) Compounds, compositions and methods useful for cholesterol mobilisation
EP2588116A4 (en) FORMULATIONS OF AN INTRAVENOUS SOLUTION OF POSACONAZOLE STABILIZED BY SUBSTITUTED BETA CYCLODEXTRIN
NZ703162A (en) Heterocyclic modulators of lipid synthesis
MX2012007935A (es) Compuestos heterociclicos fungicidas.
IN2014CN00989A (es)
WO2012006474A3 (en) Compounds and methods for inhibiting phosphate transport
MX2011012095A (es) Composiciones y metodos para tratar la isquemia y la lesion por isquemia-reperfusion.
WO2010114275A3 (ko) 다이펩타이드를 유효성분으로 포함하는 자외선에 의한 홍반반응 억제조성물
NI201200168A (es) Formulaciones farmacéuticas
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
BR112012023178A2 (pt) ramidinas substituídas como antagonistas de receptor prostaglandina 2
WO2011023367A3 (en) Bisphosphonate-prodrugs
MX2013011926A (es) Derivados de glicosido y usos de los mismos.
WO2010067987A3 (ko) 신규한 2, 6-위치에 치환된 3-니트로피리딘 유도체, 그의 제조방법 및 이를 포함하는 약학 조성물
NZ591204A (en) Pharmaceutical compositions and methods for stabilizing the same

Legal Events

Date Code Title Description
FG Grant or registration